TearLab Corporation To Release Q3-10 Financial Results On November 11, 2010
SAN DIEGO, Nov. 3, 2010 (GLOBE NEWSWIRE) -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) expects to announce its 2010 financial results for the third quarter before the market opens on Thursday, November 11, 2010.
TearLab is pleased to invite all interested parties to participate in a conference call during which time financial results will be discussed. The call will be held on November 11, 2010, at 8:30a.m. Eastern Standard Time at 877-303-6310 (within the United States and Canada).
Date: November 11, 2010 Time: 8:30 AM ET
Listen via Internet: http://www.tearlab.com/us/shareholder.htm/Schedule this webcast into MS-Outlook calendar (click open when prompted): http://apps.shareholder.com/PNWOutlook/t.aspx?m=44543&k=1CC99D1F
Telephone: (877) 303-6310For those wishing to listen to a recording of the call via telephone, a replay will be made available by 11:30am EST after the conclusion of the live call and will remain posted for a period of seven days. To listen to the recording, simply telephone (800) 642-1687 or (706) 645-9291 and enter reservation # 18561749 when prompted. About OccuLogix, Inc. dba TearLab Corporation OccuLogix dba TearLab Corporation ( www.tearlab.com) develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB.' TearLab received the CE Mark for its TearLab(TM) Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 20 countries including the US. Forward-Looking Statements This press release may contain forward-looking statements, including statements regarding the growth of the market for dry eye disease products, the impact of our product on the management of affected patients, and our intention to seek CLIA Waiver. These statements relate to future events and are subject to risks, uncertainties and assumptions about the Company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.
CONTACT: Kilmer Lucas Inc. Stephen Kilmer (President) 905 690-2400 Ext.21 email@example.com Leonard Zehr (Managing Director) 905 690 2400 Ext.41 firstname.lastname@example.org
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV